by James Dye | Apr 1, 2024 | News & Media
Beyond Employee Engagement: Unpacking Performance in Life Sciences Leadership – Executive Roundtable April 1, 2024 In this insightful episode of Conversations Life Science Leaders Aren’t Having, Jeff Harmon hosts an invaluable Life Science Executive... by James Dye | Mar 21, 2024 | News & Media
March 20, 2024/28:57/E24012 In this episode of BioTech Nation, Dr. David Bearss, President, and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered... by Halia Therapeutics | Feb 16, 2024 | News & Media
The study will enroll up to 80 adults who are undergoing the surgical removal of two or more molar teeth for inflammatory and pain management. February 16, 2024 US-based biopharmaceutical company Halia Therapeutics has begun a Phase II clinical trial to... by Halia Therapeutics | Feb 9, 2024 | News & Media
Halia Therapeutics Inc. and Canary Speech Inc. have established a collaboration in Alzheimer’s disease. This collaboration leverages Canary Speech’s artificial intelligence (AI) vocal biomarker platform, which utilizes advanced AI algorithms to analyze subtle changes... by Halia Therapeutics | Feb 1, 2024 | News & Media
Lee LandenbergerJanuary 31, 2024 Halia Therapeutics Inc. has, its CEO confidently asserts, taken an atypical road to building its infrastructure and financing. The Lehi, Utah-based company just completed a $30 million series C financing to further develop its lead... by Halia Therapeutics | Jan 17, 2024 | News & Media
Biotech Acquisitions Heat Up, Giving Venture Capitalists Hope for 2024 ‘Investors and entrepreneurs also are wrestling with questions such as the impact of the 2022 Inflation Reduction Act, which enabled Medicare to negotiate prices of certain medications, said... by Halia Therapeutics | Jan 11, 2024 | News & Media
January 11th, 2024 Author: Danny Sullivan Dr. David Bearss was featured in Longevity.Technology discussing Halia Therapeutics moving into multiple Phase 2 trials for chronic inflammation and whether the company may have created a ‘longevity drug.’ Fresh from... by Halia Therapeutics | Jan 4, 2024 | News & Media
Alternative Funding Strategies to Discuss at JPM The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that investors are excited before taking the... by Halia Therapeutics | Dec 11, 2023 | News & Media
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game changing... by Halia Therapeutics | Dec 8, 2023 | Press Releases, News & Media
The Phase II trial of HT-6184 will enroll around 50 patients with MDS who are or are on the borderline of being transfusion-dependent. Halia Therapeutics is looking to start a Phase II trial of its pipeline candidate HT-6184 in myelodysplastic syndrome (MDS) early... by Halia Therapeutics | Dec 8, 2023 | News & Media
Starting a company is interesting. I’m a scientist by training and have often considered myself the world’s most reluctant entrepreneur. Halia Therapeutics is the sixth company I’ve started, but most of the time, I still think of myself as the guy who used... by Halia Therapeutics | Nov 29, 2023 | News & Media, Press Releases
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced positive results following the... by Halia Therapeutics | Sep 19, 2023 | News & Media
“David Bearss’ passion for drug discovery has guided his noteworthy career as a dynamic leader who integrates scientific and business interests to deliver new medicines to patients. That passion is still evident today as he gives back to the industry he loves,... by Halia Therapeutics | Sep 18, 2023 | News & Media
“Halia Therapeutics believes it is on the forefront of research to target chronic inflammation to treat neurodegeneration and inflammatory diseases. Chronic inflammation causes more health issues than the average person may realize. It causes arthritis, anemia,... by Halia Therapeutics | Aug 23, 2023 | News & Media
Thanks to Salt Lake City’s FOX 13 News for attending and reporting on Halia Therapeutics’ grand opening. This report aired August 23,... by Halia Therapeutics | Aug 22, 2023 | News & Media
Halia targeting chronic inflammation to keep people healthier, living longer Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of... by Halia Therapeutics | Aug 8, 2023 | News & Media
Read the entire article at: www.bioworld.com/articles/699721-in-the-clinic-for-aug-8-2023 by Halia Therapeutics | Jun 19, 2023 | News & Media
https://podcasts.apple.com/us/podcast/episode-37-david-bearss-ph-d-president-and-ceo-of/id1648796570?i=1000616814121 David Bearss, President and CEO of Halia Therapeutics, and Todd Kays, Vice President of Dermatology at Vile Health Technologies, discuss the connection... by Halia Therapeutics | Jun 8, 2023 | News & Media
Halia Therapeutics – Eliminating Chronic Inflammation by Targeting the NLRP3 Inflammasome Dr. David Bearss, PhD, President and CEO at Halia Therapeutics, a clinical-stage biopharma company developing novel therapies to improve the lives of patients with inflammatory... by Halia Therapeutics | Mar 31, 2023 | News & Media
We are proud to announce that Halia CEO David Bearss Ph.D. will be awarded the 2023 Governor’s Medal for Science and Technology on May 2nd at the One Utah Summit. Recipients of the 2023 Utah Governor’s Science Medals...